NKGen Biotech, Inc.

NKGen Biotech, Inc., which completed its business combination with Graf Acquisition Corp. IV — a blank-check company sponsored by Graf & Company that conducted its IPO in 2021 — filed an S-1/A registration amendment on June 27, 2024, under the ticker GFOR on Nasdaq. The company operates in the clinical-stage biopharmaceutical sector, with its pipeline focused on natural killer cell-based immunotherapies targeting neurodegenerative conditions, including Alzheimer's disease. The amendment represents ongoing post-merger registration activity as NKGen Biotech establishes its public company reporting profile following the de-SPAC transaction. To access full filing timelines, sponsor profiles, and deal analytics for NKGen Biotech and the broader SPAC universe, sign up for complete data coverage at SpacDesk.